Rosty Raykov - 31 Dec 2025 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Rosty Raykov
Issuer symbol
FENC
Transactions as of
31 Dec 2025
Net transactions value
-$78,371
Form type
4
Filing time
05 Jan 2026, 16:05:16 UTC
Previous filing
05 Dec 2025
Next filing
02 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Raykov Rosty Director C/O FENNEC PHARMACEUTICALS, INC., PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK /s/ Rosty Raykov 05 Jan 2026 0001468316

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common shares Award $0 +5,208 +6.7% $0.000000 82,734 31 Dec 2025 Direct F1
transaction FENC Common shares Options Exercise $38,215 +15,598 +19% $2.45 98,332 02 Jan 2026 Direct F2
transaction FENC Common shares Sale $78,371 -10,312 -10% $7.60 88,020 02 Jan 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Stock Options Options Exercise $38,215 -15,598 -0.95% $2.45 1,618,586 02 Jan 2026 Options 15,598 $2.45 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024.
F2 Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025.
F3 Shares sold to satisfy tax obligation on option exercise.
F4 Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025.